‘Outcomes will be better’: Therapeutic drug monitoring in IBD

ORLANDO — Whether reactive or proactive, therapeutic drug monitoring has become an important part of inflammatory bowel disease care, according to experts.
Raymond K. Cross Jr., MD, director of the IBD program at the University of Maryland School of Medicine, told Healio Gastroenterology and Liver Disease that therapies in IBD can be fickle, and for many patients who initially respond, that effect will be fleeting.
“Despite having more therapies ever to treat Crohn’s disease and ulcerative colitis, at least 30% to 40% of people are not going to respond to treatment, and with

Source link

Related posts

Norfloxacin ineffective for cirrhosis survival, but beneficial in ascites


Researchers caution that expediting HLH treatment may miss underlying cancers


OncoBreak: 'Don't Be Afraid to Cry'; HPV Cancer Risk; Cannabinoids=$$$


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy